Drug-eluting stent in malignant biliary obstruction

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 16, Issue 5, 2009, Pages 628-632

  Lee, Dong Ki ^a  

^a Yonsei University   (South Korea)

Author keywords

Cholangiocarcinoma; Drug eluting stent; Malignant biliary obstruction

Indexed keywords

ANGIOPEPTIN; CARBOPLATIN; DACTINOMYCIN; DEXAMETHASONE; HALOFUGINONE; HEPARIN; HIRUDIN; ILOPROST; METALLOPROTEINASE INHIBITOR; PACLITAXEL; PACLITAXEL DERIVATIVE; PICIBANIL; PROTEINASE INHIBITOR; RAPAMYCIN; TACROLIMUS; TRANILAST; VASCULOTROPIN; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; CANCER INHIBITION; CHOLANGITIS; CHOLECYSTITIS; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG MECHANISM; DRUG RELEASE; ESOPHAGUS CANCER; HUMAN; MATERIAL COATING; NONHUMAN; OBSTRUCTIVE JAUNDICE; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BALLOON DILATION; BILE DUCT NEOPLASMS; CHOLESTASIS; DRUG-ELUTING STENTS; ENDOSCOPY, DIGESTIVE SYSTEM; FEMALE; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 70049085839     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-009-0135-1     Document Type: Article

References (24)

1. Machan L, Jessurun L, Hunter W, Arsenault L. Angiogenesis inhibitor-coated metallic stents in the porcine bile duct: Prevention of benign reactive overgrowth. Radiology. 1995;197(Suppl 1):241.
2. Machan L, Hunter W. Angiogenesis inhibition as a means to prevent stent overgrowth. J Vasc Interv Radiol. 1997;8(Suppl 1):198-9.
3. Manifold DK, Cowling M, Maynard N, Machan L, Mason R, Adam A. Paclitaxel coated stents in oesophageal adenocarcinoma. Cardiovasc Intervent Radiol. 1998;21:S129.
4. Mezawa S, Homma H, Sato T, Doi T, Miyanishi K, Takada K, et al. A study of carboplatin-coated tube for the unresectable cholangiocarcinoma. Hepatology. 2000;32:916.
5. Lee DH, Kang SG, Jeong S, Yoon CJ, Choi JA, Byun JN, et al. Local delivery system of immune modulating drug for unresectable adenocarcinoma: In vitro experimental study and in vivo animal study. Cardiovascular and inter. Cardiovasc Intervent Radiol. 2006;29:832-7.
6. Uehara K, Ichida T, Sugahara S, Ishikawa T, Yamagiwa S, Yoshida Y, et al. Systemic administration of liposome-encapsulated OK-432 prolongs the survival of rats with hepatocellular carcinoma through the induction of IFN-gamma-producing hepatic lymphocytes. J Gastroenterol Hepatol. 2002;17:81-90.
7. Okamoto M, Oshikawa T, Tano T, Ohe G, Furuichi S, Nishikawa H, et al. Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst. 2003;95:316-26.
8. Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor refection peptide. Cancer Res. 2003;63:4112-8.
9. Takahashi K, Harauchi D, Kimura S, Saito S, Monden Y. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients. Int J Immunopharmacol. 1998;20:375-88.
10. Oshikawa T, Okamoto M, Ohe G, Furuichi S, Nishikawa H, Ahmed S, et al. Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of KO-432: Comparison between the TS-2-binding and TS-2-unbinding fraction. Int Immunopharmacol. 2003;3:643-55.
11. Nishikido M, Kiyohara T, Koga S, Shindo K, Matsuya F, Saito Y, et al. OK-432-induced killer cell activity: Potential method for monitoring immunological complications after renal transplantation. Nephrol Dial Transplant. 2001;16:2067-71.
12. Itoh T, Ueda Y, Okugawa K, Fujiwara H, Fuji N, Yamashita T, et al. Streptococcal preparation OK-432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother. 2003;52:207-14.
13. Lee DK, Kim HS, Kim KS, Lee WJ, Kim HK, Won YH, et al. The effect on porcine bile duct of a metallic stent covered with a paclitaxel-incorporated membrane. Gastrointest Endosc. 2005;61:296-301.
14. Suk KT, Kim JW, Kim HS, Baik SK, Oh SJ, Lee SJ, et al. Human application of a metallic stent covered with a paclitaxel-incorporated membrane for malignant biliary obstruction: Multicenter pilot study. Gastrointest Endosc. 2007;66:798-803.
15. Lee DH. Drug-eluting stent in gastrointestinal disease. Korean J Gastroenterol. 2007;49:294-9.
16. Mani G, Feldman MD, Patel D, Agrawal CM. Coronary stents: A materials perspective. Biomaterials. 2007;28:1689-710.
17. Machan L. Clinical experience and applications of drug-eluting stents in the noncoronary vascular, bile duct and esophagus. Adv Drug Deliv Rev. 2006;58:447-62.
18. Rowinsky EK, Donehover RC. Paclitaxel (Taxol). N Engl J Med. 1995;332:1004-14.
19. Kalinowski M, Alfke H, Kleb B, Durfeld F, Joachim Wagner H. Paclitaxel inhibits proliferation of cell lines responsible for metal stent obstruction: Possible topical application in malignant bile duct obstructions. Invest Radiol. 2002;37:399-404.
20. Dhanikula AB, Panchagnula R. Localized paclitaxel delivery. Int J Pharm. 1999;183:85-100.
21. Wassef W, Syred I. Designer stents: Are we there yet? Gastrointest Endosc. 2007;66:804-8.
22. Folkman J, Hochberg M. Self-regulation of growth in three dimensions. J Exp Med. 1973;138:745-53.
23. Hunter WL, Burt HM, Machan L. Local delivery of chemotherapy: A supplement to existing cancer treatments. A case for surgical pastes and coated stents. Adv Drug Deliv Rev. 1997;26:199-207.
24. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery. J Controlled Release. 2001;70:157-67.